VNDA
Vanda Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.09
+1.49%Year over year
Reported trailing growth
- Revenue
- +6.0%
- EBITDA
- —
- EBIT
- -78.0%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +49.3%
- EBITDA
- +59.1%
- EPS
- +71.3%
Three-year CAGR
- Revenue
- -5.3%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026